<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948243</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0115</org_study_id>
    <nct_id>NCT03948243</nct_id>
  </id_info>
  <brief_title>Licorice Botanical Dietary Supplements - Metabolism and Safety in Women</brief_title>
  <official_title>Licorice Botanical Dietary Supplements - Metabolism and Safety in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human safety studies will be carried out to test whether red clover botanical dietary&#xD;
      supplements used by peri- and post-menopausal women are safe to use with Food and Drug&#xD;
      Administration (FDA)-approved drugs. To test this, a red clover dietary supplement&#xD;
      (previously tested in women at the University of Illinois at Chicago without any harmful&#xD;
      effects) will be given with four selected FDA-approved drugs to determine if the Licorice&#xD;
      supplement can increase or decrease how these medications are absorbed, metabolized and&#xD;
      excreted by the human body. Preclinical studies predict that the licorice supplement might&#xD;
      affect the metabolism or break down of these probe drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the start of a study, subjects will be administered low doses of a mixture of four&#xD;
      FDA-approved drugs (caffeine, tolbutamide, dextromethorphan, and alprazolam), and serial&#xD;
      blood samples will be drawn and analyzed for the concentration of each drug over time.&#xD;
      Afterwards, participants will take the licorice dietary supplement twice daily for 14 days to&#xD;
      allow for potential inhibition or induction of drug metabolizing enzymes and transporters.&#xD;
      Thereafter, the same drugs will be taken again to obtain a second measure of drug&#xD;
      concentrations in blood over time. Changes in the concentration-time curve values for each&#xD;
      probe drug obtained before and after ingestion of the supplement would indicate that&#xD;
      metabolism of the probe drugs is impacted by the licorice dietary supplement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Area Under the Curve (AUC)</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate area under the (extrapolated) concentration-time curve to determine any changes compared to pre-intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Apparent Clearance</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate apparent clearance of probe drug to determine any changes compared to pre-intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Peak Concentration</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate peak concentration of probe drug to determine any changes compared to pre-intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Time for Peak Concentration</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate time for peak concentration of probe drug to determine any changes compared to pre-intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Drug Half-life [Time Frame: baseline and 14 days]</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate half-life of probe drug to determine any changes compared to pre-intervention.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Food-drug Interaction</condition>
  <arm_group>
    <arm_group_label>G.Glabra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Licorice</intervention_name>
    <description>Experimental :G.Glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days</description>
    <arm_group_label>G.Glabra</arm_group_label>
    <other_name>G.Glabra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam 2 MG</intervention_name>
    <description>substrate</description>
    <arm_group_label>G.Glabra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine 100 MG</intervention_name>
    <description>substrate</description>
    <arm_group_label>G.Glabra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolbutamide 250 mg</intervention_name>
    <description>substrate</description>
    <arm_group_label>G.Glabra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan 30mg</intervention_name>
    <description>substrate</description>
    <arm_group_label>G.Glabra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy peri- and post-menopausal women ages 40 - 79&#xD;
&#xD;
          -  non-smokers&#xD;
&#xD;
          -  no-significant medical conditions as assessed by subject-reported medical history,&#xD;
             physical examination and blood and urine chemistry screens&#xD;
&#xD;
          -  no medical condition that requires chronic use of medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergies or hypersensitivity to caffeine, dextromethorphan, sulfonylureas&#xD;
             (tolbutamide), benzodiazepines, or licorice&#xD;
&#xD;
          -  positive pregnancy test&#xD;
&#xD;
          -  use of hormone therapy within 8 weeks of study initiation for oral agents, 4 weeks for&#xD;
             transdermal or other topical agents&#xD;
&#xD;
          -  use of caffeine products 7 days before study participation or during the study&#xD;
&#xD;
          -  use of citrus products 7 days before study participation or during the study&#xD;
&#xD;
          -  other prescription (with the exception of the MirenaÂ® IUD) or non-prescription&#xD;
             medicines within the 2 weeks prior to study initiation or during the study&#xD;
&#xD;
          -  chronic diseases, such as inflammatory bowel disease, that could alter the absorption&#xD;
             or metabolism of the probe substrates&#xD;
&#xD;
          -  unwillingness to comply with study requirements&#xD;
&#xD;
          -  current participation in another clinical trial&#xD;
&#xD;
          -  CYP2D6 deficiency based on phenotyping at screening&#xD;
&#xD;
          -  smoker&#xD;
&#xD;
          -  licorice (whether as a botanical dietary supplement, candy, food, drink or otherwise)&#xD;
             within the previous two weeks and during the study&#xD;
&#xD;
          -  use of any dietary supplements within the last 2 weeks prior to study initiation and&#xD;
             during the study&#xD;
&#xD;
          -  extreme obesity (defined as &gt;40 BMI)&#xD;
&#xD;
          -  alcohol or drug abuse&#xD;
&#xD;
          -  chronic diseases such as diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard vanBreemen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Elena Barengolts</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Licorice</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolbutamide</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

